Infectious Disease Diagnostics Market Regional Insights

Market Momentum & Strategic Outlook

The global Infectious Disease Diagnostics Market is projected to reach USD 42.20 billion by 2030, up from USD 26.58 billion in 2025, growing at a CAGR of 9.7% during the forecast period. This strong growth trajectory reflects the rising prevalence of infectious diseases worldwide and the increasing demand for reliable, rapid, and accurate diagnostic tools. Heightened global awareness of pandemic preparedness, antimicrobial resistance, and point-of-care testing has accelerated innovation and adoption across both developed and emerging healthcare systems.

The market is also witnessing significant strategic movements by key players aimed at strengthening decentralized and molecular diagnostics capabilities. In July 2024, F. Hoffmann-La Roche Ltd. (Switzerland) acquired LumiraDx’s infectious disease technology, expanding its decentralized testing portfolio and advancing global access to rapid diagnostics. Similarly, in November 2023, Abbott (US) received FDA approval for its Alinity m High Risk HPV assay, enhancing its molecular diagnostics range for infectious disease detection. These strategic steps underline a broader industry shift toward integrated testing ecosystems that combine high-throughput laboratory systems with accessible point-of-care solutions.

Regional Analysis

North America currently holds the largest share of the infectious disease diagnostics market, driven by advanced healthcare infrastructure, strong regulatory frameworks, and high adoption of molecular and immunodiagnostic technologies. The United States remains a key innovation hub, supported by government funding and private investment in diagnostic R&D.

Europe represents a mature but steadily growing market, characterized by strong emphasis on early disease detection, antimicrobial resistance monitoring, and public health initiatives. Countries such as Germany, the UK, and France are major contributors to this growth.

The Asia-Pacific (APAC) region is emerging as the fastest-growing market, propelled by rising infectious disease burden, expanding healthcare access, and supportive government policies. Countries like China, India, South Korea, and Japan are investing heavily in local manufacturing and diagnostic innovation, particularly in molecular testing and rapid diagnostics. Additionally, the proliferation of public-private partnerships is enabling regional diagnostic capacity-building and technology transfer.

Latin America and the Middle East & Africa (MEA) are experiencing growing market participation, supported by initiatives from global diagnostic companies to strengthen local distribution networks and improve testing accessibility in underserved regions.

Country Coverage

At the country level, the United States dominates global market share due to its advanced molecular diagnostic capabilities and strong commercial presence of industry leaders like Abbott, Danaher, and Thermo Fisher Scientific. In Europe, Germany and France lead in clinical diagnostic adoption, while China represents the largest and fastest-growing market in the Asia-Pacific region, driven by government-led healthcare modernization and pandemic response preparedness. India is another notable growth center, with companies such as Molbio Diagnostics and Trivitron Healthcare advancing affordable, portable diagnostic solutions for emerging markets.

Key Highlights by Stakeholders

• F. Hoffmann-La Roche Ltd. strengthened its global footprint through the acquisition of LumiraDx’s infectious disease technology (2024), enhancing decentralized testing capabilities.
• Abbott received FDA approval for the Alinity m HR HPV assay (2023), expanding its molecular diagnostics portfolio.
• Danaher Corporation, through subsidiaries such as Cepheid and Beckman Coulter, continues to scale up high-throughput automated testing platforms globally.
• bioMérieux (France) is expanding its syndromic testing and clinical microbiology solutions, particularly targeting antimicrobial resistance surveillance.
• Thermo Fisher Scientific (US) remains a key enabler of workflow automation and next-generation molecular technologies.
• Regional players like Molbio Diagnostics (India) and SD Biosensor (South Korea) are enhancing point-of-care diagnostic access in low- and middle-income countries through portable and rapid testing kits.

Industry Trends

Key trends shaping the market include:

• Integration of AI and machine learning for faster and more accurate test interpretation.
• Expansion of molecular point-of-care platforms for rapid detection of respiratory and sexually transmitted infections.
• Syndromic panel testing gaining traction for simultaneous identification of multiple pathogens.
• Growing demand for home-based and decentralized diagnostics post-COVID-19.
• Investment in next-generation sequencing (NGS) and CRISPR-based assays for early and precise pathogen identification.

Questions Answered by the Market

Q1. What drives demand for infectious disease diagnostics?
The market is driven by the rising global prevalence of infectious diseases, increased R&D investments, technological innovation in molecular and rapid testing, and the need for early, accurate diagnosis to manage outbreaks effectively.

Q2. Which region leads in adoption?
North America leads in technology adoption, while Asia-Pacific is witnessing the fastest growth due to expanding healthcare infrastructure and government support for diagnostic innovation.

Q3. What strategies are companies adopting to stay competitive?
Companies are pursuing mergers, acquisitions, and partnerships, along with investments in digital diagnostics, decentralized testing, and data-driven healthcare models.

Q4. What are the emerging trends?
Emerging trends include AI-driven diagnostics, syndromic panel testing, portable molecular testing platforms, and sustainability-focused diagnostic manufacturing.

Q5. What is the long-term outlook?
With continuous technological advancement and increased focus on public health preparedness, the infectious disease diagnostics market is expected to sustain robust growth through 2030, becoming a key enabler of global healthcare resilience.

Check out Related Reports to Infectious Disease Diagnostics

Veterinary Infectious Disease Diagnostics Market

Companion Diagnostics Market